Confidential Treatment Requested by BIND Therapeutics, Inc. THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENTOption and License Agreement • December 17th, 2015 • BIND Therapeutics, Inc • Pharmaceutical preparations
This THIRD AMENDMENT TO THE RESEARCH, OPTION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of December 8, 2015 (the “Third Amendment Effective Date”), by and between BIND Therapeutics, Inc. (as successor in interest to BIND Biosciences, Inc.) (“BIND”) and Pfizer Inc. (“Pfizer”) and amends that certain Research, Option and License Agreement between BIND Biosciences, Inc. and Pfizer, dated as of March 25, 2013 (the “Agreement”) and amended and restated as of June 12, 2013 and March 31, 2015. Capitalized terms used herein without definition herein shall have the meaning given such terms in the Agreement.
